Streetbeat News

Price Targets

ACXP

HC Wainwright & Co. analyst Ed Arce has reaffirmed a Buy rating on Acurx Pharmaceuticals (NASDAQ:ACXP) and increased the price target from $13 to $14, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 11:36 am

COGT

HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on Cogent Biosciences (NASDAQ:COGT) but has lowered the price target from $27 to $13.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 11:34 am

RPHM

HC Wainwright & Co. analyst Mitchell Kapoor has downgraded Reneo Pharmaceuticals (NASDAQ:RPHM) from Buy to Neutral and significantly reduced the price target from $30 to $1.5.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 11:30 am

MYO

HC Wainwright & Co. analyst Sean Lee has initiated coverage on Myomo (AMEX:MYO) with a Buy rating and set a price target of $6.5 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 11:27 am

ZION

Baird analyst David George has downgraded Zions Bancorp (NASDAQ:ZION) from Outperform to Neutral and set a price target of $45.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 11:25 am

USB

Baird analyst David George has downgraded U.S. Bancorp (NYSE:USB) from Outperform to Neutral and set a price target of $52. This reflects a change in Baird's outlook on the stock, suggesting a more cautious stance on U.S. Bancorp's future stock performance.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 11:24 am

AYX

Needham analyst Mike Cikos has reaffirmed a Buy rating on Alteryx (NYSE:AYX) and increased the price target from $42 to $56, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 11:06 am

G

Baird analyst David Koning has downgraded Genpact (NYSE:G) from Outperform to Neutral and set a price target of $38. This reflects a more cautious stance on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 11:01 am

RPHM

Jefferies analyst Eun Yang has downgraded Reneo Pharmaceuticals (NASDAQ:RPHM) from Buy to Hold and significantly reduced the price target from $17 to $1.8.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 10:53 am

CHWY

Needham analyst Anna Andreeva has maintained a Buy rating on Chewy (NYSE:CHWY) and increased the price target from $20 to $25, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 10:51 am